A NEW IMNOVID^® (pomalidomide) TRIPLET

IMNOVID with bortezomib
and dexamethasone, PVd

NOW APPROVED IN THE EU

for RRMM as early as first relapse, post-REVLIMID^®
(lenalidomide)¹

Indication
IMNOVID in combination with bortezomib and
dexamethasone is indicated in the treatment of adult
patients with multiple myeloma who have received at
least one prior treatment regimen including lenalidomide.

RRMM=relapsed/refractory multiple myeloma.

LEARN MORE

References: 1. IMNOVID [Summary of Product Characteristics]. Utrecht, Netherlands, Celgene Europe B.V.; 2019. 2. Dimopoulos M, et al. ASH 2018. Abstract no. 3278.

PVd=IMNOVID+bortezomib+ dexamethasone.

03/19 INT-POMA190004

PVd is the first and only triplet specifically
proven in a 100% REVLIMID-exposed RRMM
population as early as first relapse.²